Vorapaxar Sulfate

Sold as Zontivity. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Vorapaxar Sulfate (sold as Zontivity), first approved May 8, 2014, with 0 new uses approved and 0 published complete response letters.

First approved: May 8, 2014
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $0K
First approved in the EU: Jan 19, 2015

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Zontivity	Part D	$0K	-100%	0

Approvals in the EU (EMA)

First approved in the EU 8 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals

Zontivity, new substanceMerck Sharp Dohme Limited · Jan 19, 2015 · withdrawn

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
May 8, 2014	ZontivityNDA 204886 · New molecular entity	Key Therap	3	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA